Sophiris Bio Inc. (NASDAQ: SPHS) is a clinical-stage biopharmaceutical company focused on developing innovative products for the treatment of urological diseases.

Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.

Sophiris Bio has reported top-line interim data from a multi-center, open label, Phase 2b study evaluating the safety and efficacy of targeted intraprostatic administration of topsalysin for the treatment of histologically proven, clinically significant, localized prostate cancer.